logo

For the Inventor, By the Inventor

Arcadia, CA, United States of America

Lili Yang

This inventor holds 18 USPTO granted patents and 9 published patent applications and 6 EPO patents, primarily in Gene Therapy. Top assignees: California Institute of Technology, University of California. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lili Yang. Retrieved from https://idiyas.com/inventor/lili-yang-4r4u251s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 77.8

 

Average Co-Inventor Count = 3.1

ph-index = 7

Forward Citations = 132(Granted Patents)


Location History:

  • Pasadena, CA (US) (2011 - 2014)
  • Arcadia, CA (US) (2012 - 2020)
  • Los Angeles, CA (US) (2021)

Company Filing History:

goldMedal16 out of 4,629 
 
California Institute of Technology
 patents
silverMedal4 out of 16,035 
 
University of California
 patents
where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Gene Delivery
T Cell Receptors
Invariant Natural Killer T Cells
Pseudotyped Lentivirus
Viral Vectors
Dendritic Cell Vaccination
Retrovirus
Antigen-Specific Lymphocytes
Immune Response
Polypeptides
Human B Lymphopoiesis
18 patents (USPTO):Explore Patents
1. 12617834 - COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES (2026-05-05),
2. 12187777 - Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof (2025-01-07),
3. 10927160 - Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof (2021-02-23),
4. 10696984 - Packaging cell for making a pseudotyped lentivirus (2020-06-30),
5. 10266847 - Methods of delivering a pseudotyped lentivirus (2019-04-23),
6. 9994867 - Method of targeting gene delivery using viral vectors (2018-06-12),
7. 9840721 - Recombinant retrovirus pseudotyped with E2 alphavirus glycoprotein (2017-12-12),
8. 9540657 - Expression of secreted and cell-surface polypeptides (2017-01-10),
9. 9303072 - Method of stimulating an immune response using a pseudotyped lentivirus (2016-04-05),
10. 8906359 - Recombinant retrovirus pseudotyped with a E2 alphavirus glycoprotein (2014-12-09),
11. 8821856 - Method of targeted gene delivery using viral vectors (2014-09-02),
12. 8552150 - MART-1 T cell receptors (2013-10-08),
13. 8372390 - Recombiant lentivirus comprising an E2 alphavirus glycoprotein that binds to DC-SIGN (2013-02-12),
14. 8329162 - Targeted gene delivery for dendritic cell vaccination (2012-12-11),
15. 8273345 - Targeted gene delivery to dendritic cells (2012-09-25),

Title: Lili Yang: Innovator in Immunotherapy

Introduction

Lili Yang is a prominent inventor based in Arcadia, CA (US), known for her groundbreaking work in the field of immunotherapy. With a total of 18 patents, she has made significant contributions to the development of engineered invariant natural killer T (iNKT) cells, which have the potential to revolutionize cancer treatment.

Latest Patents

Among her latest patents, Yang has disclosed methods for engineering invariant natural killer T (iNKT) cells using hematopoietic stem and progenitor cells (HSPCs). These engineered iNKT cells are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. The patents also include iNKT TCR nucleotide sequences and codon-optimized sequences for expression, showcasing her innovative approach to enhancing immune responses.

Career Highlights

Lili Yang has had a distinguished career, working at prestigious institutions such as the California Institute of Technology and the University of California. Her research has focused on harnessing the power of the immune system to combat diseases, particularly cancer, through the engineering of immune cells.

Collaborations

Throughout her career, Yang has collaborated with notable scientists, including David Baltimore and Pin Wang. These partnerships have further advanced her research and contributed to the field of immunotherapy.

Conclusion

Lili Yang's contributions to the field of immunotherapy through her innovative patents and collaborations highlight her as a leading figure in the development of advanced cancer treatments. Her work continues to inspire future research and innovation in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…